{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 45,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "thesis_headline",
  "function": "frame_situation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/3",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.25,
        "y": 0.3
      },
      "kind": "image",
      "text": "Imara logo to Enliven logo transition",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6f34e0f-3522-4c6c-9642-f815d78e8e99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Enliven Therapeutics opportunity: Provides Imara shareholders with opportunity to participate in the Enliven growth story, at a pivotal time for Enliven. Diversified and clinical-stage portfolio: Two parallel lead programs currently in development, ELVN-001, a highly selective BCR-ABL inhibitor for Chronic Myeloid Leukemia, and ELVN-002, a highly selective HER2 and pan-HER2 mutant irreversible inhibitor for HER2-driven cancers, as well as additional programs in the research pipeline. Multiple near-term milestones: Planned steady stream of company milestones, including early Phase 1 data for ELVN-001 expected by the end of 2023. Strong balance sheet supports runway into 2026: Combined company expected to have approximately $300 million in cash and cash equivalents upon closing; resources expected to fund operations into early 2026",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc33d7eb-d470-408f-9e01-588849aab627",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "title",
      "text": "Transition into a clinical-stage, precision oncology company with multiple shots on goal",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93e2c045-4970-4d0b-87bc-e30d94bfb6be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "Merger with Imara Has the Potential to be Transformative for Enliven",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b31976c-1a13-499b-8e3c-2fdd07d81e9c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 5,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a2a27cc7-e663-48ea-b40c-b53e7024a7e2",
      "evidence": "The document presents the merger as a way to create a clinical-stage, precision oncology company with multiple opportunities for growth and innovation.",
      "position": 1,
      "objective": "Why is precision oncology important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}